Alnylam Pharmaceuticals said this week that it and collaborators have developed a novel class of lipid nanoparticles capable of greater target inhibition than the company's existing lipid delivery agents.
According to the company, the so-called reLNPs demonstrate “potent target gene silencing in vivo, with an ED50 at doses of less than 0.05 mg/kg while demonstrating tolerability at doses exceeding 10 mg/kg.”
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
